Blog

Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding its expression and stability. This study, led by Seán Mac Fhearraigh, PhD, investigates how inhibiting EZH2 (Enhancer of Zeste Homolog 2) enhances PD-L1 protein stability, with the deubiquitinase USP22 (ubiquitin-specific peptidase 22) identified as a key regulator in this process. The findings provide valuable insights into potential therapeutic strategies for improving cancer treatment outcomes.Study SummaryThe research highlights a novel interaction between EZH2 inhibition and PD-L1 expressio …

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune evasion and tumor biology remains a focal point of investigation. The immune system, with its remarkable ability to recognize and eliminate malignant cells, is often thwarted by various mechanisms employed by tumors to evade detection. Among the myriad of proteins involved in this complex interplay, USP22 (Ubiquitin Specific Peptidase 22) has emerged as a significant player. This deubiquitinating enzyme is not only pivotal in regulating protein stability but also plays a crucial role in modulatin …